# A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Source: https://onco.cc/trials/nct03767244/  
OnCo record `nct03767244` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Apalutamide in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy is a phase 3 interventional study registered as NCT03767244 by Janssen Research & Development, LLC, with 2517 participants enrolled, started 2019-06-11 and due to reach its primary completion in 2026-12-01. Interventions recorded: Apalutamide, Androgen Deprivation Therapy (ADT) and Placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03767244
- Phase: 3
- Setting: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 2517

## Sources

- ClinicalTrials.gov NCT03767244: https://clinicaltrials.gov/study/NCT03767244

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Apalutamide](https://onco.cc/drugs/apalutamide/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct03767244.json